CAS: 39741-62-3; H-Gln-Otbu.Hcl

相似化合物

422324-35-4 56-85-9 6899-04-3

(2S)-5-Oxo-2,5-Bis(Phenylmethoxycarbonylamino)Pentanoic Acid,叔丁醇,4-二甲氨基吡啶,盐酸 以75%的收率获得产物
参考文献:Csanady,G.;Medzihradszky,K.,Org. Prep. And Proced. Int.,20,(1988) N 1-2,180-184
标题:Csanady,G.;Medzihradszky,K.,Org. Prep. And Proced. Int.,20,(1988) N 1-2,180-184

专利信息

专利号:WO-2025118133-A1
优先权日:2023-12-05
标题 :(s)-lenalidomide-5-derivative, synthesis method therefor and use thereof
发明人：ZHENG RUI; Xiang Kuirong; WANG YIFENG; ZHU XUXIN; DU YIHUI; DING WEI; SHU LEI; CAI LEI
权利人:ZHEJIANG APELOA JIAYUAN PHARMACEUTICAL CO LTD; APELOA SHANGHAI PHARMA SOLUTIONS CO LTD; APELOA PHARMACEUTICAL CO LTD
摘要:Disclosed in the present invention are an (S)-lenalidomide-5-derivative, a synthesis method therefor, and a use thereof. The use comprises the following steps: removing a tert-butoxycarbonyl protecting group from a compound 1 under an acidic condition to obtain a compound 2; adding a benzyloxycarbonyl protecting group to the compound 2 in the presence of an organic amine to obtain a compound 3; subjecting the compound 3 to a reductive amination reaction with L-glutamine tert-butyl ester to obtain a compound 4; subjecting the compound 4 to a ring-closure reaction under an acidic condition to obtain a compound 5; subjecting the compound 5 to a hydrogenation and benzyloxycarbonyl removal reaction with hydrogen under an acidic condition under the action of a hydrogenation catalyst to obtain a compound 6; and subjecting the compound 6 to a reductive amination reaction with a compound 7 to obtain a compound 8. The compounds 5, 6, and 8 are (S)-lenalidomide 5-derivatives. The synthesis method of the present invention has simple post-treatment, less racemization and high yield, does not generate toxic pollutants, and is environmentally friendly and safe.

专利号:US-9795613-B2
优先权日:2014-12-10
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL; GLYNN DANIEL; MILLS MARK
权利人:CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9187522-B2
优先权日:2011-12-12
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC
摘要:The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9598430-B2
优先权日:2013-06-11
标 题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC; CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.